Press releases

Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

Read This Press Release

Scholar Rock Announces Publication of Preclinical Pharmacology, Pharmacokinetics, and Safety Profile of SRK-181 in the International Journal of Toxicology

Read This Press Release

Scholar Rock Announces the Addition of Joshua Reed to Its Board of Directors

Read This Press Release

Scholar Rock Announces Issuance of U.S. Patent Protecting Add-On or Combination Therapy with a Myostatin Inhibitor for the Treatment of Spinal Muscular Atrophy

Read This Press Release

Scholar Rock Presents TOPAZ Interim Analysis Data for Apitegromab in Spinal Muscular Atrophy at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference

Read This Press Release

Scholar Rock Reports Full Year 2020 Financial Results and Highlights Business Progress

Read This Press Release

Scholar Rock Announces Senior Management Promotions

Read This Press Release

Scholar Rock Presents Preclinical Data for SRK-181 at the TGFβ for Immuno-Oncology Drug Development Summit

Read This Press Release